Biomarkers | CHOP Research Institute
 

Biomarkers

The study goal is to risk stratify pediatric (Acute Respiratory Distress Syndrome) ARDS patients and to identify sub-phenotypes with shared biology in order to appropriately target therapies in future trials.

The mission of the Clinical Pharmacology RAG is to support CHOP investigators engaged in clinical pharmacology research, foster collaborations within the CHOP/Penn research community, and create additional educational opportunities for trainees.

The Lurie Family Foundations MEG Imaging Center uses advanced imaging methods to study brain development, autism spectrum disorder, and mild traumatic brain injury/concussion.

This study is looking to recruit CHOP patients 5-30 years old with suspected/ confirmed bone sarcomas. The study is looking to evaluate a new MRI technique to evaluate bones and any mass in them.

Vancomycin is a commonly administered antibiotic in critically ill children, but it can have unwanted side effects on the kidney (acute kidney injury).

The goal of this study is to identify unique characteristics in the way kids and teens with Autism Spectrum Disorder (ASD) speak in comparison to typically developing peers.

The mission of the Stress Neurobiology Research Program is to further the understanding of the neural basis of individual differences in response to stressful experiences.

The Lynch Lab conducts clinical, translational, and basic science research on the rare disease Friedreich ataxia

Research in the Hartung Lab focuses on genetic kidney diseases, particularly autosomal recessive polycystic kidney disease (ARPKD).

The Vanderver Lab uses a translational, multi-stakeholders research model to investigate underlying causes and clinical manifestations of leukodystrophies and other related white matter disorders, in order to support meaningful advances in the diagnosis and treatment of these conditions.